Back to Search Start Over

Selecta Presents Phase 1 Clinical Data for Lead Product Candidate, SEL-212, in Patients with Hyperuricemia at 11th Annual IMVAC Summit SEL-212 Designed to be First Non-Immunogenic Uricase Therapeutic for Severe Gout Data Show Substantial and Sustained Reduction of Serum Uric Acid Levels for 30 Days or Longer After Single Dose Company to Host Conference Call Tomorrow Morning

Selecta Presents Phase 1 Clinical Data for Lead Product Candidate, SEL-212, in Patients with Hyperuricemia at 11th Annual IMVAC Summit SEL-212 Designed to be First Non-Immunogenic Uricase Therapeutic for Severe Gout Data Show Substantial and Sustained Reduction of Serum Uric Acid Levels for 30 Days or Longer After Single Dose Company to Host Conference Call Tomorrow Morning

Source :
Plus Company Updates. December 28, 2016
Publication Year :
2016

Abstract

Watertown: Selecta Biosciences, Inc. has issued the following press release: Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company developing a novel class of targeted antigen-specific immune therapies, today announced that [...]

Details

Language :
English
Database :
Gale General OneFile
Journal :
Plus Company Updates
Publication Type :
News
Accession number :
edsgcl.475460777